Mid‐dose mifepristone (25 mg‐50 mg) leads to lower observed number of pregnancies (all women) compared with low‐dose mifepristone (< 25 mg) (high certainty).
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher any side effect compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ nausea compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in specific side effects ‐ vomiting compared with low‐dose mifepristone (< 25 mg) (moderate certainty).
Mid‐dose mifepristone (25 mg‐50 mg) leads to higher specific side effects ‐ spotting/bleeding after treatment compared with low‐dose mifepristone (< 25 mg) (high certainty).
Mid‐dose mifepristone (25 mg‐50 mg) showed no clear difference in menses ‐ early compared with low‐dose mifepristone (< 25 mg) (low certainty).
Mid‐dose mifepristone (25 mg‐50 mg) probably leads to higher menses ‐ delay compared with low‐dose mifepristone (< 25 mg) (moderate certainty).